2023 Research Articles

Related

• Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation  PMID: 36822371
  • “In patients with chronic constipation, the vibrating capsule was superior to placebo in improving bowel symptoms and quality of life. The vibrating capsule was safe and well tolerated.”
• The Gut Microbial Bile Acid Modulation and its Relevance to Digestive Health and Diseases  PMID: 36841488
• Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome  PMID: 36221245

Overview

• Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO  PMID: 36985147
• Small Intestinal Bacterial Overgrowth PMID: 31536241

Causes/ Risk Factors  
Drugs/medication

• Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care PMID: 36943203
• Decongestants, proton pump inhibitors, and systemic antibiotics are associated with an increased occurrence of dysbiosis PMID: 36594656

​Pathophysiology

• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome PMID: 36573834
• Altered gut microbiota in patients with small intestinal bacterial overgrowth  PMID: 36180941

Associated Conditions
Celiac Disease

• Celiac disease in Chilean adults doi.org/10.1016/j.rgmxen.2022.03.007

​Covid-19 NEW

• SIBO: the trail of a new human pathology associated with multiple severe and disabling Covid-19 and long Covid symptoms or induced by the anti-Covid-19 vaccine  PMID: 36762752
• Post-COVID-19 Gastro-Intestinal Disturbances PMID: 36464877

Ehlers-Danlos syndrome

• Low prevalence of positive hydrogen breath tests in patients with functional gastrointestinal conditions and hypermobile Ehlers-Danlos syndrome PMID: 36989174

IBD

• Impact of Small Intestinal Bacterial Overgrowth in Patients with Inflammatory Bowel Disease and Other Gastrointestinal Disorders-A Retrospective Analysis in a Tertiary Single Center and Review of the Literature PMID: 36769583

IBS

• Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology PMID: 36961659
  

Gallbladder Polyps NEW

• Small Intestinal Bacterial Overgrowth in Patients with Gallbladder Polyps: A Cross-Sectional Study PMID: 36883124

Lactose Intolerance

• Lactase Deficiency Diagnosed by Endoscopic Biopsy-based Method is Associated With Positivity to Glucose Breath Test PMID: 36606439
• Efficacy of incremental loads of cow's milk as a treatment for lactose malabsorption in Japan PMID: 36818633

Liver Disease

• Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? PMID: 36986052
• Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis  PMID: 36902037
• Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study PMID: 36985296

Parkinson’s disease

• Berlin Bowel Bothers: Might Adolf Hitler's Gut Problems Have Been Parkinson-Related? PMID: 36921591

Stroke NEW

• Risk factors for small intestinal bacterial overgrowth in patients with acute ischaemic stroke  PMID: 36762525
  • “The prevalence of SIBO in patients with AIS (acute ischemic stroke) was 28.8 %. TG (triglycerides) and Hcy (homocysteine) levels are independent risk factors for SIBO in patients with AIS. Both markers had good predictive value for the occurrence of SIBO.” 
    

Systemic Sclerosis

• A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis PMID: 36792109

Testing
Breath Testing

• Plasma levels of intestinal Fatty-Acid Binding protein (I-FABP), abdominal distension and hydrogen concentration after lactitol SIBO test PMID: 36926907
• UNDERSTANDING OUR TESTS: HYDROGEN-METHANE BREATH TESTING TO DIAGNOSE SMALL INTESTINAL BACTERIAL OVERGROWTH PMID: 36744854

Methane

• Prevalence of methanogens and associated factors in patients with irritable bowel syndrome and healthy controls in a Southeastern Mexican population  PMID: 34863643

Treatment

• Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth PMID: 36830173

Antibiotics: Rifaximin

• Efficacies of prokinetics and rifaximin on the positivity of a glucose breath test in patients with functional dyspepsia: a randomized trial  PMID: 35748472
• Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice PMID: 36658488

Herbal Antibiotics 

• Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study) PMID: 36873985

Probiotics

• "Impact of Saccharomyces boulardii CNCM I-745 on bacterial overgrowth and composition of intestinal microbiota in IBS-D patients: results of a randomized pilot study"  PMID: 36630947
  • "In patients with SIBO, S. boulardii CNCM I-745, associated with dietary advice, reduced bacterial overgrowth and improved digestive symptoms while restoring the intestinal microbiota....The safety of S. boulardii was excellent. "
    

Prokinetics

• Efficacies of prokinetics and rifaximin on the positivity of a glucose breath test in patients with functional dyspepsia: a randomized trial  PMID: 35748472
• A Review of the Cardiovascular Safety of Prucalopride in Patients with Chronic Idiopathic Constipation PMID: 3692795
• Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies PMID: 36876155
• Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation: secondary analysis of a randomized controlled trial PMID: 36662303 
  • In a real-world European CV (cardiovascular) safety study among 35,087 patients (prucalopride, 5,715; polyethylene glycol 3350 [PEG3350], 29,372), results were consistent for no evidence of increased risk of major adverse CV events among patients treated with prucalopride vs PEG3350. Studies to date have not raised concerns regarding the impact of prucalopride treatment on CV parameters."